Abstract: Novel antagonists of MCP proteins, in particular of MCP-1 protein, can be obtained by generating MCP mutants whose GAG binding site, located at the N-terminal of MCP proteins, is eliminated following non-conservative substitutions. Compounds prepared in accordance with the present invention can be used in the treatment or prevention of diseases related to an undesirable activity of MCP proteins such, such as inflammatory disease, autoimmune diseases, vascular diseases, and cancer.

Abstract: Mutants of CC chemokines, which contain at least two mutations in the cationic site of the 40's loop and which, relative to the wild-type molecule, have a reduced GAG-binding activity. In particular it has been found that such mutated chemokines are effective in the treatment of multiple sclerosis and/or demyelinating diseases. A triple mutant of RANTES is the compound showing the best results.

Abstract: The oral efficacy of C—C chemokines containing a dibasic site in the 40's conserved cationic sequence, such as RANTES and MIP-1?, is improved by substituting at least one of the residues in the dibasic site in a non-conservative manner.

Abstract: This invention relates to therapeutic, diagnostic and/or prophylactic formulations and dosages of anti-CD3 antibodies, as well as to methods for using such formulations and dosages.

Abstract: Novel antagonists of MCP proteins, in particular of MCP-1 protein, can be obtained by generating MCP mutants whose GAG binding site, located at the N-terminal of MCP proteins, is eliminated following non-conservative substitutions. Compounds prepared in accordance with the present invention can be used in the treatment or prevention of diseases related to an undesirable activity of MCP proteins such, such as inflammatory disease, autoimmune diseases, vascular diseases, and cancer.

Abstract: Novel antagonists of CXCR3-binding CXC chemokines, and in particular of human CXCL11, can be obtained by generating mutants of such chemokines in which the binding to glycosaminoglycans (GAGs) is impaired due to non-conservative substitutions of amino acids involved in this interaction. Compounds prepared in accordance with the present invention can be used to block the activity of CXCR3-binding CXC chemokines on CXCR3-expressing cells, thereby providing therapeutic compositions for use in the treatment or prevention of diseases related to excessive activated T cells migration, such as graft rejection and autoimmune diseases, and of diseases needing an increase of vascularization, such as ischemic heart disease.

Abstract: The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Abstract: This invention provides method of treatment of autoimmune diseases and/or inflammatory disorders.

Abstract: The oral efficacy of C—C chemokines containing a dibasic site in the 40's conserved cationic sequence, such as RANTES and MIP-1?, is improved by substituting at least one of the residues in the dibasic site in a non-conservative manner.

Abstract: Mutants of specific CC-chemokines containing a non-conservative substitution in a conserved consensus sequence act as CC-chemokine antagonists, and can be effectively used in the treatment of autoimmune and inflammatory diseases, cancers, and viral or bacterial infections. Particularly preferred are the RANTES/CCL5 mutants having the amino acid sequence of SEQ ID NO: 1, 2, 3, or 4.

Abstract: The invention relates to the use of inhibitors of IL-18 in the preparation of a medicament for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity.

Abstract: Mutants of CC chemokines, which contain at least two mutations in the cationic site of the 40's loop and which, relative to the wild-type molecule, have a reduced GAG-binding activity. In particular it has been found that such mutated chemokines are effective in the treatment of multiple sclerosis and/or demyelinating diseases. A triple mutant of RANTES is the compound showing the best results.